Lisa Thomas, MD
Hematology & Oncology · Dunmore, PANPI 1346239894
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.2%), speaking fees and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Incyte Corporation at 37.6% of the total. Reporting peaked in 2024 at $3,445 and has fallen 87.2% since, to $441 in 2025.
Across 43 payments — averaging $159.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$3K
- Seagen Inc.$2K
- AstraZeneca$677
- Varian Medical Systems, Inc.$480
- Janssen Scientific Affairs, LLC$340
- Astellas Pharma US Inc$215
- plus $877 from 20 others
What the payments were for
- Consulting fees$3,92557%
- Speaking & faculty fees$1,39520%
- Travel & lodging$2624%
- Food & beverage$5718%
- Education$70710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 1 | $2,580 |
| Seagen Inc. | 4 | $1,692 |
| AstraZeneca | 4 | $677 |
| Varian Medical Systems, Inc. | 1 | $480 |
| Janssen Scientific Affairs, LLC | 1 | $340 |
| Astellas Pharma US Inc | 3 | $215 |
| Exelixis Inc. | 2 | $200 |
| Sanofi-aventis U.S. LLC | 1 | $91 |
| Lilly USA, LLC | 1 | $79 |
| Sobi, Inc | 1 | $75 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| Pfizer | 2 | $52 |
| Johnson & Johnson | 2 | $46 |
| GSK | 2 | $42 |
| Novartis | 2 | $38 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Merck | 1 | $22 |
| AbbVie | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $16 |
| Array Biopharma Inc | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Sanofi | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Advanced Oxygen Therapy Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,861 in reported general payments places this provider in the 70th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 57 | $782,530 |
| TasignaNilotinib Hcl | 19 | $374,131 |
| ImbruvicaIbrutinib | 19 | $287,339 |
| CabometyxCabozantinib S-Malate | 14 | $269,233 |
| Lenalidomide | 23 | $266,280 |
| CalquenceAcalabrutinib Maleate | 15 | $229,595 |
| EliquisApixaban | 88 | $78,583 |
| XareltoRivaroxaban | 72 | $71,866 |
| Abiraterone Acetate | 27 | $34,135 |
| Anastrozole | 336 | $8,616 |
| Hydroxyurea | 59 | $1,941 |
| Letrozole | 69 | $1,497 |
| Hydrocortisone | 52 | $988 |
| Warfarin Sodium | 78 | $773 |
| Escitalopram Oxalate | 50 | $613 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $52 | $861,114145 claims |
| NovartisTasigna | $38 | $374,13119 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $16 | $287,33919 claims |
| Exelixis Inc.Cabometyx | $200 | $269,23314 claims |
| AstraZenecaCalquence | $677 | $229,59515 claims |
| Johnson & JohnsonXarelto | $46 | $71,86672 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $340 | $34,13527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Dunmore
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.